The Food and Drug Administration has approved Moderna’s mFLUSIVA, the first mRNA-based seasonal influenza vaccine cleared in the United States. The authorization opens a new use for the technology widely associated with COVID-19 vaccines, but it comes with an important split: adults ages 50 to 64 received traditional approval, while the indication for people 65 and older was granted accelerated approval pending a study confirming clinical benefit.
Moderna expects the vaccine, previously known as mRNA-1010, to be available for eligible Americans in the 2026-27 respiratory-virus season. The decision matters because adults 65 and older bear a disproportionate risk of severe influenza, hospitalization and death. Yet the accelerated pathway means the regulatory evidence for that older group is not the same as a completed demonstration that the shot reduces flu illness better than existing options.
A first for mRNA, with two approval standards
mFLUSIVA is authorized to prevent influenza caused by the influenza A subtypes and influenza B strains represented in the vaccine among people 50 and older, according to Moderna’s product announcement. Independent coverage by the University of Minnesota’s Center for Infectious Disease Research and Policy also described it as the first FDA-approved mRNA flu shot.
The age distinction is more than a technical footnote. For adults 50 through 64, FDA granted what is generally called traditional approval. For people 65 and older, FDA used accelerated approval, a mechanism that can allow a product onto the market on the basis of a surrogate measure judged reasonably likely to predict benefit, while requiring postmarketing confirmation.
For mFLUSIVA, the older-adult authorization rests on immune-response evidence, and continued approval may depend on a confirmatory trial that verifies and describes clinical benefit. Healthcare Dive reported that Moderna plans to conduct that study over two flu seasons. The company is expected to compare the vaccine with a high-dose influenza vaccine in adults 65 and older, a relevant question because high-dose products are commonly used in that age group.
This does not mean the vaccine is unavailable to seniors or that its safety is unproven. It means the type of evidence supporting the authorization differs by age. An immune response can be an important predictor, but it is not identical to a trial result showing fewer laboratory-confirmed flu cases, hospitalizations or other clinical outcomes in the population being studied.
What the reported trial result shows — and does not
News reports describe a Moderna trial involving more than 40,000 adults 50 and older during the 2024-25 respiratory-virus season. CNN reported that mFLUSIVA was about 27% more effective than a standard-dose flu vaccine, while other accounts characterized the result differently. ABC News described 27% fewer confirmed flu cases among participants ages 50 to 64; Healthcare Dive referred to a 27% reduction in influenza-like illness.
Those descriptions point to an approximate advantage of similar size, but they should not be treated as interchangeable without the underlying trial report or FDA review. The available accounts do not provide the full study protocol, case definition, absolute illness rates, confidence intervals or detailed subgroup findings. In particular, “influenza-like illness” can be broader than laboratory-confirmed influenza.
The comparison also was with a standard-dose influenza vaccine. It does not establish that mFLUSIVA outperforms every licensed flu vaccine, including high-dose vaccines used by many people 65 and older. The planned confirmatory study is intended to address a more clinically relevant comparison for that population.
A 27% relative difference, if confirmed in a published analysis, would also need context from the season in which it was measured. Flu vaccine performance varies with the viruses circulating, how closely the vaccine strains match them, the age and health of recipients, and the outcome measured. A result from one season does not by itself guarantee the same advantage in future seasons.
Why manufacturers see potential in the platform
Conventional flu vaccines are generally made through a production process that begins well before the Northern Hemisphere’s flu season. Vaccine-strain selection is necessarily a forecast. mRNA vaccines use genetic instructions that prompt cells to make a selected viral protein, rather than delivering the protein itself, and manufacturers say the approach can shorten the interval between choosing strains and producing doses.
That could permit later strain selection and potentially improve the match between a vaccine and viruses that ultimately circulate, as CNN noted. But faster manufacturing is a potential operational advantage, not proof of better real-world protection. Whether it translates into a consistent clinical advantage will depend on future studies and on how flu viruses evolve each season.
The route to approval was not entirely smooth. Reporting by ABC News and CNN said FDA initially declined to review Moderna’s application in February, then agreed to do so after the company committed to an additional postmarketing study. In June, Moderna said an FDA vaccine advisory committee unanimously supported a favorable benefit-risk assessment.
Safety findings and the next public-health steps
Reported side effects were broadly similar to those seen with other vaccines that stimulate a strong short-term immune response: injection-site reactions, fatigue, headache, muscle or joint pain, chills, nausea or vomiting, and fever. ABC News reported that reactions occurred more often with mFLUSIVA than with the standard-dose comparator, though they were generally mild and lasted two days or less. Moderna lists severe allergic reactions as a rare potential risk.
FDA staff reviewers and Moderna identified no new or serious safety concerns in the materials described by Healthcare Dive. Still, as with other newly authorized vaccines, safety monitoring after use begins is part of the evidence base, particularly as use expands across different age groups and health conditions.
Federal authorization alone does not settle how broadly the shot will be used. The Centers for Disease Control and Prevention’s advisory process had not completed a recommendation specific to mFLUSIVA in the available reports. For the coming season, the vaccine will add an mRNA option for eligible adults while the required study tests whether its immune-response evidence in people 65 and older is borne out in clinical outcomes.